The DC–T cell axis is an effective target for the treatment of non‐small cell lung cancer

Abstract

The dendritic cell (DC)‐T cell axis is a bridge that connects innate and adaptive immunities. The initial immune response against tumors is mainly induced by mature antigen‐presenting DCs. Enhancing the crosstalk between DCs and T cells may be an effective approach to improve the immune response to non‐small cell lung cancer (NSCLC). In this article, a review was made of the interaction between DCs and T cells in the treatment of NSCLC and how this interaction affects the treatment outcome.

The immune microenvironment of lung adenocarcinoma featured with ground‐glass nodules

“…cDC induce cellular and humoral immunity by forming MHC I/CD8 or MHC II/CD4 immunological synapses with initial T cells, while pDC produce large amounts of IFN‐γ, thereby accelerating innate and adaptive immunity and thus suppressing tumor progression 63 Comparatively, lung tumors also cause DC to express immunosuppressive markers and can even be reprogrammed to convert cDC into DCreg to evade immune surveillance. 64 , 65 In addition, DCreg can induce a higher proportion of Tregs to maintain immune tolerance, 66 which may potentially hinder tumor clearance in lung cancer TIME.…”